Getting from 'Close' to 'Cigar' Via Alternate Splicing
Antisense Oligonucleotide Helps Severe Spinal Muscular Atrophy
By Anette Breindl
Monday, March 14, 2011
Scientists at Isis Pharmaceuticals Inc., with both industrial colleagues from Genzyme Corp. and academic colleagues from Cold Spring Harbor Laboratory and Harvard Medical School, have managed to improve the symptoms of spinal muscular atrophy (SMA) in a mouse model of the disorder by treating the animals with an antisense oligonucleotide. The work, Frank Bennett, Isis senior vice president of research, told BioWorld Today, "sets the stage for going forward into the clinic" with the compound, which the company hopes to do later in 2011.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.